Semaglutide (Wegovy, Ozempic, and Rybelsus) Semaglutide is in a category of prescription drugs called glucagon-like peptide-1 agonists, or GLP-1s, and they have upended the way obesity is treated
Notably, the target who lost weight and maintained it was rated more favorably (i.e., higher in positive traits, lower in negative traits, less unhealthy) than all three of the targets who currently had obesity (i.e., targets from the GLP-1 regain , diet+exercise regain , and no weight loss conditions), suggesting that having a higher weight is harshly stigmatized regardless of a persons prior weight loss attempts
If you would like to live a healthier lifestyle, lose weight, or manage a metabolic condition like diabetes, Virta Health may be able to help
Identifying drug side effects could complement the phase IV medication data collected through the FDA and create a novel strategy to leverage social media data to uncover potential new side effects or a higher frequency of previously described side effects
